Provided by Tiger Trade Technology Pte. Ltd.

Vanda Pharmaceuticals

4.63
-0.1800-3.74%
Post-market: 4.58-0.0500-1.08%19:47 EDT
Volume:1.45M
Turnover:6.75M
Market Cap:279.94M
PE:-1.00
High:4.85
Open:4.85
Low:4.57
Close:4.81
52wk High:9.94
52wk Low:4.27
Shares:60.46M
Float Shares:47.66M
Volume Ratio:0.84
T/O Rate:3.04%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.6291
EPS(LYR):-3.7413
ROE:-77.81%
ROA:-22.38%
PB:1.27
PE(LYR):-1.24

Loading ...

Vanda Pharmaceuticals Balances Strong Growth With Rising Losses

TIPRANKS
·
Aug 06

Vanda Pharmaceuticals Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Vanda Pharmaceuticals Q2 Loss Widens on Lower Sales, Higher Costs

Reuters
·
Aug 06

Vanda Pharma Q2 EPS $(1.04) Misses $(0.59) Estimate, Sales $50.529M Miss $61.925M Estimate

Benzinga Earnings
·
Aug 06

Vanda Q2 GAAP Net Loss Widens to $62.5 Million; Revenue Falls 3.9% to $50.53 Million

Reuters
·
Aug 06

Vanda Pharmaceuticals Q2 EPS USD -1.04

THOMSON REUTERS
·
Aug 06

Vanda Pharmaceuticals Inc Expected to Post a Loss of 59 Cents a Share - Earnings Preview

Reuters
·
Aug 04

Vanda Pharmaceuticals Schedules Q2 Earnings Release and Conference Call

Reuters
·
Jul 30

Analysts Are Bullish on Top Healthcare Stocks: Vanda (VNDA), Celldex (CLDX)

TIPRANKS
·
Jul 22

Vanda Reports Positive Opinion for Imsidolimab Orphan Drug Label

MT Newswires Live
·
Jul 17

Vanda announces EMA positive opinion for orphan drug designation of Imsidolimab

TIPRANKS
·
Jul 17

Vanda Says EMA Panel Backs Orphan Drug Designation for Imsidolimab in Generalized Pustular Psoriasis

Reuters
·
Jul 17

Vanda Pharmaceuticals - Imsidolimab Bla for Gpp Under FDA Review with Target Action Date December 12, 2026

THOMSON REUTERS
·
Jul 17

Vanda Pharmaceuticals - Announces Ema Positive Opinion for Orphan Drug Designation of Imsidolimab for Gpp

THOMSON REUTERS
·
Jul 17

Vanda Says FDA Grants Rare Pediatric Disease Designation for CMT2S Therapy Vca-894a

Reuters
·
Jul 08

Vanda Pharmaceuticals Inc: Advancing Development of Its Investigational Therapy for Cmt2s

THOMSON REUTERS
·
Jul 08

Vanda Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Investigational Therapy for Charcot-marie-tooth Disease Type 2S

THOMSON REUTERS
·
Jul 08

Vanda Pharmaceuticals SVP, General Counsel and Secretary Daniel McGuire files initial beneficial ownership statement

Reuters
·
Jun 09

Vanda Pharmaceuticals Inc - Japan Grants Orphan Drug Designation to Imsidolimab for Generalized Pustular Psoriasis

THOMSON REUTERS
·
May 27

Japan health ministry grants orphan drug status to Vanda’s imsidolimab for pustular psoriasis

Reuters
·
May 27